News
Clinical Trials Start for Stroke Drug Developed by Scripps Research Institute, USC, and ZZ Biotech
Experimental drug may extend window for effective stroke treatment LA JOLLA, CA, August 8, 2012 — Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Research Institute and the University of Southern California (USC) and further developed by biotech company ZZ Biotech. The clinical…
Read MoreZZ Biotech Initiates Phase 1 Study with 3K3A-APC for the Treatment of Acute Ischemic Stroke
HOUSTON, Texas, August 8, 2012—ZZ Biotech, LLC today announced that it has commenced dosing healthy volunteers in a Phase 1 clinical study with 3K3A-APC, a recombinant variant of human activated protein C (APC), being developed for the treatment of acute ischemic stroke. The Phase 1 study is a randomized, double-blind, placebo-controlled, single-center trial that will…
Read MoreExperimental Drug May Extend Therapeutic Window for Stroke
Clinical safety trials in humans to start this summer LOS ANGELES, July 17, 2012 — A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally approved clot-busting therapy. Clinical trials to test…
Read More